Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 153, Issue 2, 2000, Pages 525-526

  Nozue, Tsuyoshi ^a,b,c   Nohara, Atsushi ^a   Higashikata, Toshinori ^a   Inazu, Akihiro ^a   Mabuchi, Hiroshi ^a   Kajinami, Kouji ^a   Koizumi, Junji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; MEVINOLIN; NICORANDIL; NIFEDIPINE; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL; WARFARIN;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED;

EID: 0034515457     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00626-2     Document Type: Letter

References (9)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
4. Cholesterol reduction and its impact on coronary artery disease and total mortality
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Drug treatment of lipid disorders
7. Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors
8. Defined daily doses in relation to hypolipidemic efficacy of lovastatin, pravastatin, and simvastatin
9. The rule of 5 and the rule of 7 in lipid lowering by statin drugs